<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    PDL BioPharma, Inc.

    PDL BioPharma, Inc.

    PDL BioPharma (NASDAQ: PDLI) seeks to provide a significant return for its shareho...

    PDL BioPharma (NASDAQ: PDLI) seeks to provide a...

    Filing Type:    PU
    Immunomedics, Inc.

    Immunomedics, Inc.

    Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal a...

    Immunomedics is a clinical-stage biopharmaceuti...

    Filing Type:    PU
    UroGen Pharma Ltd.

    UroGen Pharma Ltd.

    UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company developing advanc...

    UroGen Pharma Ltd. is a clinical-stage biopharm...

    Filing Type:    PU
    Jounce Therapeutics, Inc.

    Jounce Therapeutics, Inc.

    Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transfo...

    Jounce Therapeutics is a clinical stage immunot...

    Filing Type:    PU
    T2 Biosystems, Inc.

    T2 Biosystems, Inc.

    T2 Biosystems, a leader in the development and commercialization of innovative med...

    T2 Biosystems, a leader in the development and ...

    Filing Type:    PU
    Jasperate, Inc.

    Jasperate, Inc.

    Jasperate, Inc. is a startup company in the truest sense. We have a strong managem...

    Jasperate, Inc. is a startup company in the tru...

    Amount Raised:    $99,400.00
    Fundraising Status:    EC
    Filing Type:    CF
    Fate Therapeutics, Inc.

    Fate Therapeutics, Inc.

    We are a biopharmaceutical company dedicated to the development of programmed cell...

    We are a biopharmaceutical company dedicated to...

    Filing Type:    PU
    BeyondSpring, Inc.

    BeyondSpring, Inc.

    Headquartered in New York, BeyondSpring Inc. (BeyondSpring) is a global, clinical-...

    Headquartered in New York, BeyondSpring Inc. (B...

    Filing Type:    PU
    Atara Biotherapeutics, Inc.

    Atara Biotherapeutics, Inc.

    Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...

    Atara Biotherapeutics is a leading off-the-shel...

    Filing Type:    PU
    Five Prime Therapeutics, Inc.

    Five Prime Therapeutics, Inc.

    Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to im...

    Five Prime Therapeutics, Inc. discovers and dev...

    Filing Type:    PU
    Genomic Health, Inc.

    Genomic Health, Inc.

    Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-bas...

    Genomic Health, Inc. (NASDAQ: GHDX) is the worl...

    Filing Type:    PU
    Celcuity Inc.

    Celcuity Inc.

    Celcuity is a cellular analysis company that is discovering new cancer sub-types a...

    Celcuity is a cellular analysis company that is...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.